| Therapy-educated mesenchymal stem cells enrich for tumor-initiating cells M Timaner, N Letko-Khait, R Kotsofruk, M Benguigui, O Beyar-Katz, ... Cancer research 78 (5), 1253-1265, 2018 | 87 | 2018 |
| Copper oxide nanoparticles inhibit pancreatic tumor growth primarily by targeting tumor initiating cells M Benguigui, IS Weitz, M Timaner, T Kan, D Shechter, O Perlman, S Sivan, ... Scientific Reports 9 (1), 12613, 2019 | 78 | 2019 |
| Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer KA Khan, JL Ponce de Léon, M Benguigui, P Xu, A Chow, W Cruz-Muñoz, ... NPJ Breast Cancer 6 (1), 29, 2020 | 30 | 2020 |
| Current challenges in metastasis research and future innovation for clinical translation AL Parker, M Benguigui, J Fornetti, E Goddard, S Lucotti, ... Clinical & Experimental Metastasis 39 (2), 263-277, 2022 | 19 | 2022 |
| Copper oxide loaded PLGA nanospheres: towards a multifunctional nanoscale platform for ultrasound-based imaging and therapy O Perlman, IS Weitz, SS Sivan, H Abu-Khalla, M Benguigui, Y Shaked, ... Nanotechnology 29 (18), 185102, 2018 | 16 | 2018 |
| The potential role of immune alteration in the cancer–covid19 equation—a prospective longitudinal study T Goshen-Lago, M Szwarcwort-Cohen, M Benguigui, R Almog, ... Cancers 12 (9), 2421, 2020 | 10 | 2020 |
| Interferon-stimulated neutrophils as a predictor of immunotherapy response M Benguigui, TJ Cooper, P Kalkar, S Schif-Zuck, R Halaban, ... Cancer Cell 42 (2), 253-265. e12, 2024 | 7 | 2024 |
| Dose-and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach M Benguigui, D Alishekevitz, M Timaner, D Shechter, Z Raviv, S Benzekry, ... Oncotarget 9 (2), 2574, 2018 | 7 | 2018 |
| Long-term Immunogenicity of BNT162b2 vaccine in patients with solid tumors I Waldhorn, R Holland, T Goshen-Lago, M Benguigui, M Halberthal, ... JAMA oncology 8 (6), 940-941, 2022 | 3 | 2022 |
| Chemotherapy-induced tumor immunogenicity is mediated in part by megakaryocyte-erythroid progenitors A Vorontsova, TJ Cooper, J Haj-Shomaly, M Benguigui, S Levin, ... Oncogene 42 (10), 771-781, 2023 | 2 | 2023 |
| Bv8 blockade sensitizes Anti-PD1 therapy resistant tumors M Benguigui, A Vorontsova, M Timaner, S Levin, J Haj-Shomaly, A Deo, ... Frontiers in Immunology 13, 903591, 2022 | 2 | 2022 |
| A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma. Y Shaked, M Benguigui, R Halaban, A Bacchiocchi, I Kamer, J Bar, ... Journal of Clinical Oncology 41 (16_suppl), 2557-2557, 2023 | 1 | 2023 |
| Predicting immunotherapy response TJ Cooper, Y Shaked, MR Benguigui US Patent App. 18/140,177, 2023 | | 2023 |
